John Ferguson, VP of Pharmacovigilance at Novartis Vaccines and Diagnostics, examines today’s drug safety landscape.
Christopher Carey of Bristol-Myers Squibb shares what’s driving adoption of enterprise risk management across the pharmaceutical industry.
BY James E. Matheson, Chairman, SmartOrg, Inc. E: jmatheson@smartorg.com